$MLYS News

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...

Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Q2 Earnings Call Highlights

Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date

What to Know About This Mineralys Insider Sale Before a December FDA Date

A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger

Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?

What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision

Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor

Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock

Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Significant Reductions In Six Of Eleven Heart Failure Risk Biomarkers

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)